Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

NCT02819804 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02819804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02819804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Terminated
Start date
August 17, 2017
Completion date
August 30, 2018
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1, recurrent adult acute lymphoblastic leukemia, recurrent childhood acute lymphoblastic leukemia, refractory adult acute lymphoblastic leukemia, refractory childhood acute lymphoblastic leukemia